Nitiloop Ltd.

Developed as a fully disposable advanced surgical robot to streamline endovascular procedures, LIBERTY robotic system’s unique remote controller is developed based on feedback from the hands-on experience of physicians Microbot Medical has received a design patent allowance from the US Patent and Trademark Office (USPTO), covering the interface design of a remote controller for its LIBERTY Robotic System. The US-based company developed LIBERTY as a fully disposable advanced surgical robot with remote operation capabilities, to streamline endovascular procedures. The unique remote controller for the LIBERTY robotic system is developed based on feedback from the hands-on experience of physicians during its development. Microbot Medical general manager and chief technology officer Simon Sharon said: “The evolution of the feedback generated during development, lab and pre-clinical settings has resulted in continued improvement over the years. “We wanted to perfect the remote controller so as to replicate the hand motion during endovascular procedures, and to streamline the interaction with the guidewire, microcatheter and guiding catheter to shorten the time of endovascular procedures.” Last month, Microbot Medical acquired certain assets from vascular support micro-catheters developer Nitiloop to strengthen its LIBERTY robotic system portfolio. The acquisition included the US Food and Drug Administration (FDA) approved family of microcatheters, NovaCross CTO, NovaCross Xtreme and NovaCross BTK. The NovaCross family of microcatheters are intended for the placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions (CTO), prior to PTCA or stent intervention. When integrated with Microbot Medical’s One and Done technology, the microcatheters are expected to create procedure-related kits customised for the LIBERTY Robotic System. The integration is expected to advance endovascular procedures, while eliminating constraints to access and adoption of robotics in the endovascular space, said the company. Microbot Medical chairman, president, and CEO Harel Gadot then said: “The addition of Nitiloop’s innovative, FDA-cleared microcatheter family complements the unique robotic ecosystem we are establishing for endovascular procedures. “This is expected to further assist us in executing our strategic plan of becoming a complete procedure-based company, allowing Microbot Medical to be competitive across the entire endovascular robotic space. “We believe the NovaCross family of products, once integrated into our existing technology platforms with the LIBERTY Robotic System and our future One & Done technology, will potentially standardise endovascular procedures globally and may finally allow accessibility to robotic technology for the millions that are in dire need of life-saving treatment.”

October 12, 2022—Microbot Medical Inc. recently announced that it has acquired the assets of Nitiloop Ltd., including the FDA-cleared NovaCross family of microcatheters (NovaCross CTO for chronic total occlusion treatment; NovaCross Xtreme; and NovaCross BTK for below-the-knee treatment). The NovaCross devices are intended to facilitate the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions before percutaneous transluminal coronary angioplasty or stent intervention. According to Microbot, the NovaCross microcatheter family, as a standalone device or when potentially integrated with the company’s One & Done technology, is expected to create a collection of procedure-related kits that are customized for the Liberty robotic system. Liberty is a disposable endovascular robotic system that features remote operation capabilities and small footprint designed to reduce the requirement of capital investment and catheterization lab space. In December 2019, Microbot announced the launch the Liberty fully disposable robotic system for use in neurovascular, cardiovascular, and peripheral vascular procedures. Microbot stated that the integration of technologies, such as the NovaCross microcatheter family, is part of the company’s strategy to be competitive in the robotic field as well as the instruments market for endovascular procedures, with the aim to integrate imaging and big data capabilities. Subsequently, Microbot announced on October 11 that, along with the acquisition of the endovascular assets of Nitiloop and other developments regarding the Liberty robotic system, it has made the strategic decision to suspend the continued research and development of its Self-Cleaning Shunt (SCS) project, effective immediately. The company is planning to focus its strategic efforts on the growing endovascular space and advancing the Liberty robotic system to achieve its regulatory and commercial milestones, as well as expanding the Liberty ecosystem. The company’s plans are to explore opportunities with the SCS assets, which may include seeking buyers for the assets, entering into joint ventures, licensing arrangements, spinning-off the assets into a new operating company, or discontinuing the project altogether.

Integration with the LIBERTY Robotic System & One & Done Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market through the Expansion of Robotic Ecosystem for Endovascular Procedures The Company expects this integration to help revolutionize and standardize the way endovascular procedures are conducted. (Credit: Piron Guillaume on Unsplash) Microbot Medical announced today, as a continuation of its recent regulatory and future commercialization activities, together with its strategic mission to enable accessibility to multiple endovascular procedures globally, that it has acquired the assets of privately-held Nitiloop Ltd. The acquisition includes the NovaCross family of Microcatheters (NovaCross CTO, NovaCross Xtreme and NovaCross BTK), a U.S. Food and Drug Administration (FDA) cleared family of medical devices intended to facilitate the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions (CTO), prior to PTCA or stent intervention. The NovaCross Microcatheter family, as a standalone device or when potentially integrated with the Company’s One & Done technology, is expected to create a collection of procedure related kits that are customized for the LIBERTY Robotic System. The LIBERTY Robotic System is the first-ever disposable endovascular robotic system with remote operation capabilities and small footprint designed to reduce the requirement of capital investment and Cath Lab space. The Company expects this integration to help revolutionize and standardize the way endovascular procedures are conducted, while eliminating barriers to access and increasing the adoption rate of robotics in the endovascular space. The integration of technologies, such as the NovaCross Microcatheter family, fits well with the ecosystem strategy of the Company by allowing it to be competitive in the robotic as well as the instruments market for endovascular procedures, with the aim to integrate imaging and big data capabilities in the future. The Company believes the achievement of the LIBERTY Robotic System ecosystem will allow Microbot Medical to advance the adoption of robotics in the endovascular space, globally. “The addition of Nitiloop’s innovative, FDA cleared microcatheter family complements the unique robotic ecosystem we are establishing for endovascular procedures. This is expected to further assist us in executing our strategic plan of becoming a complete procedure-based company, allowing Microbot Medical to be competitive across the entire endovascular robotic space,” commented Harel Gadot, Chairman, President and CEO. “We believe the NovaCross family of products, once integrated into our existing technology platforms with the LIBERTY Robotic System and our future One & Done technology, will potentially standardize endovascular procedures globally and may finally allow accessibility to robotic technology for the millions that are in dire need of life-saving treatment.” Source: Company Press Release